| Studies indicate that concurrent inhibition of proto-oncogene protein B-raf (BRAF) and Map kinase kinase (MEK) improved the most effective therapeutic modality as compared as single BRAF or MEK inhibition for patients with metastatic melanoma (MM). | skin, |
| v-raf murine sarcoma viral oncogene homolog B (BRAF) is preferentially mutated in proximal colon cancers. | sarcoma,colorectal, |
| BRAF(V600E) mutation induces MGL ligand expression, thereby providing a direct link between oncogenic transformation and aberrant expression of immunosuppressive glycans in colorectal neoplasms. | colorectal,neoplasm, |
| Data show that B-Raf proto-oncogene (BRAF) V600E mutation was identified in 4 of 27 thyroid nodule patients with isthmic lesion. | thyroid, |
| This study sought to investigate the correlations of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutations with the clinicopathologic features of papillary thyroid carcinoma | sarcoma,thyroid, |
| Data suggest that combination of proto-oncogene protein B-raf (BRAF) and mTOR serine-threonine kinase (mTOR) inhibition forms the basis of a treatment regimen of thyroid cancer. | thyroid, |
| Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. | skin, |
| KRAS and BRAF oncogenes have roles in colorectal cancer development and therapy resistance [review] | colorectal, |
| Results contribute to the characterization of leukemic B cells, as it shows that upregulation of Kv1.3 in pathologic B lymphocytes is linked to the oncogenic B-RAF signaling. | leukemia, |
| Data indicate that mutations in PTEN phosphatase A167T and NRAS protein Q61L, and proto-oncogene protein BRAF V600E were detected in melanoma cell line. | skin, |
| Data indicate that among classic and follicular variant papillary thyroid carcinomas (PTCs), mutation of proto-oncogene protein B-raf (BRAF(V600E)) was significantly associated with the smaller size. | thyroid, |
| Clinical data suggest that BRAF mutations define specific subsets of patients with NSCLC; while their oncogenic nature is yet to be established in lung cancer, especially for non-V600E mutations, the value of BRAF mutations to predict the efficacy of targeted agents remains unclear. | lung, |
| Specific inhibition of BRAF oncogene, MEK or p38 signaling was associated with decreases in DIO3 expression in papillary thyroid cancer cells | thyroid, |
| Immunohistochemistry is an accurate method to evaluate BRAF proto-oncogene is papillary thyroid cancer. | thyroid, |
| these data highlight the poor prognosis of patients with metastatic melanoma and BM, despite a targetable _driver_ oncogene mutation(BRAFv600) and evidence of initial drug-responsiveness | skin, |
| Rare mutations in KRAS, NRAS, and BRAF oncogenes have been found in patients with melanoma and colorectal neoplasms. | skin,colorectal,neoplasm, |
| Data suggest that HMGCS1 (HMG-CoA synthase 1) signals through ketogenesis/acetoacetate to promote cell proliferation and BRAF(V600E)-dependent MEK1 activation in BRAF(V600E)-positive melanoma and colon cancer cells; HMGCS1 co-localizes with HMGCL (HMG-CoA lyase) and BRAF(V600E) in cytosol of melanoma and colon cancer cells. (BRAF = proto-oncogene protein B-raf) | skin,colorectal, |
| Results indicate specific and compensatory functions for proto-oncogene B-Raf (BRAF) and proto-oncogene c-RAF (CRAF) and highlight an addiction to RAF signalling in NRAS-driven melanoma. | skin, |
| expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis | lung, |
| Persistent oncogenic Braf signaling is sufficient to induce widespread DNA methylation and colorectal neoplasia. | colorectal, |